

Panel Majority Backs Olanzapine for Teen Use

BY ELIZABETH MEHCATIE

ADELPHI, MD. — The majority of a Food and Drug Administration advisory panel agreed that the data on the atypical antipsychotic olanzapine indicated that it was effective and had an acceptable safety profile for treating two pediatric indications: schizophrenia and bipolar mania in patients aged 13-17 years.

At a meeting of the FDA's Psychopharmacologic Drugs Advisory Committee, the panel voted 11-5, with 2 abstentions, that olanzapine had been shown to be effective as a treatment for schizophrenia in this age group, with the majority—10 panelists—voting that it had been shown to be "acceptably safe" for this indication. However, four of the panelists voted no on the safety question and four abstained, citing concerns that

included the well-known metabolic effects of olanzapine.

The panel also voted 17-0, with 1 abstention, that the drug had been shown to be effective for treating bipolar mania, and voted 11-4, with 3 abstentions, that it had been shown to be acceptably safe in this age group for this indication.

Those voting positively on safety and efficacy for both indications said that they considered the drug as a second-

line treatment, because of its metabolic effects. If approved, the label would advise clinicians to consider drugs before this one, because of concerns over its metabolic effects, Dr. Thomas Laughren, director of the FDA's division of psychiatry products, said at the meeting.

Olanzapine is marketed as Zyprexa by Eli Lilly and Co., and is approved for treating schizophrenia and bipolar dis-

Boston University School of Medicine

and

Pediatric News / Family Practice News

JOINTLY SPONSOR

Pediatric Infectious Diseases in the Headlines

A Continuing Medical Education Conference

October 24 – 25, 2009
Royal Sonesta Hotel, Cambridge, MA

Topic Highlights:

- What Is The Diagnosis? with James H. Brien, DO
- Influenza Challenges: Diagnosis, Treatment, Resistance, and Immunization
- CaMRSA – Diagnosis, Treatment, and Prevention
- Otitis Media – Is There Consensus About Treatment and Prevention?
- The Child With Stridor – Diagnosis and Management
- EBV: Diagnosis, Complications, and Complex Cases
- Impact of the Rotavirus Vaccine on Rotavirus Disease
- Malaria: Recognition and Management
- HPV Vaccine: What Have We Learned?
- Next Steps in Preventing Meningococcal Disease in Children
- Next Generation Pneumococcal Vaccines
- Does Probiotic Use Limit Certain Infections?
- New Challenges for Travelers
- Hectic Fevers in the First Year of Life
- Vaccine Safety
- STD Guidelines



Target Audience: This conference is designed for pediatricians, family practitioners, general practitioners, nurse practitioners, residents, and allied health professionals.

Accreditation: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine and *Pediatric News/Family Practice News*. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this educational activity for a maximum of **12.25 AMA PRA Category 1 Credit(s)**[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Continuing Medical Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Application for CME credit has been filed with the American Academy of Family Physicians. **Determination of credit is pending.**

Educational Objectives: Through participation in case discussions, small group workshops, and attendance at lectures, participants will be able to:

- Apply evidence-based practices concerning immunization across the pediatric life-span
- Identify less commonly seen travel-acquired diseases
- Improve identification and treatment of various pediatric infectious diseases

Register Now!



Course Directors

Jerome O. Klein, MD
Professor of Pediatrics, Boston University School of Medicine
Visiting Physician, Boston Medical Center

Stephen I. Pelton, MD
Professor of Pediatrics, Boston University School of Medicine
Director, Section of Pediatric Infectious Diseases, Boston Medical Center

Guest Faculty

James H. Brien, DO
Associate Professor and Head, Pediatric Infectious Diseases Section
Scott White Memorial Hospital
Texas A&M University College of Medicine

Boston University School of Medicine / Boston Medical Center Faculty

Elizabeth D. Barnett, MD
Associate Professor of Pediatrics
Director, International Clinic, Section of Pediatric Infectious Diseases

Howard Bauchner, MD
Professor of Pediatrics and Public Health
Director, Division of General Pediatrics

Ellen R. Cooper, MD
Professor of Pediatrics
Medical Director, Diagnostic Evaluation Unit, Section of Pediatric Infectious Diseases

Marisol Figueira, MD
Assistant Professor of Pediatrics
Section of Pediatric Infectious Diseases

Kenneth Grundfast, MD
Chief, Department of Otolaryngology – Head and Neck Surgery
Professor and Chairman, Otolaryngology – Head and Neck Surgery

Katherine Hsu, MD, MPH
Assistant Professor of Pediatrics
Section of Pediatric Infectious Diseases

Carole H. Moloney, RN, MSN, CPNP
Clinical Instructor, Department of Pediatrics

Colin D. Marchant, MD
Associate Professor of Pediatrics
Section of Pediatric Infectious Diseases

Vishakha Sabharwal, MD
Instructor of Pediatrics

Sandra K. Schumacher, MD, MPH
Fellow, Section of Pediatric Infectious Diseases

To register, please contact:

**Boston University School of Medicine
Continuing Medical Education**

72 East Concord Street, A305
Boston, MA, 02118

Phone: (617) 638-4605

Toll-free: (800) 688-2475

Fax: (617) 638-4905

E-mail: cme@bu.edu

Website: www.bu.edu/cme

Panel Supports Quetiapine for Pediatric Use

ADELPHI, MD. — The atypical antipsychotic quetiapine is safe and effective for treating schizophrenia in adolescents and bipolar mania in both children and adolescents between the ages of 10 and 17 years, according to a Food and Drug Administration advisory panel.

At a meeting in June, the FDA's Psychopharmacologic Drugs Advisory Committee voted 17-1 that data on quetiapine showed it was effective for treating schizophrenia in adolescents aged 13-17 years. The panel also voted 16-0, with 2 abstentions, that the drug was "acceptably safe" for treating schizophrenia in this population.

The panel voted 17-0, with 1 abstention, that the drug was effective in treating bipolar mania in children and adolescents aged 10-17 years, and voted 13-0, with 5 abstentions, that it was safe in this group. A concern among those abstaining was safety in children aged 10-12.

The FDA usually follows the recommendations of its advisory panels.

Quetiapine is marketed as Seroquel by AstraZeneca Pharmaceuticals LP. The company presented results of three studies: two short-term studies and a safety study that followed 505 of these patients for 6 months.

One study compared 400 mg or 600 mg of quetiapine per day with placebo in 284 patients aged 10-17 years who had bipolar I mania. The patients were treated for 3 weeks. Changes in the Young Mania Rating Scale from baseline to day 21, the primary efficacy end point, were significantly greater in those on quetiapine than in those on placebo.

The second study comprised 222 patients aged 13-17 years, who had schizophrenia and were treated with 400 mg or 800 mg per day of quetiapine or placebo for 6 weeks. Changes in the Positive and Negative Syndrome Scale, which measures the severity of different components of schizophrenia, were significantly greater in those taking quetiapine.

In the two short-term studies, somnolence was the most common adverse event, affecting almost half of the patients on quetiapine and lasting for a mean of 12 days.

—Elizabeth Mehcatie

order in adults.

Eli Lilly presented the results of a short-term study of 107 patients aged 13-17 with schizophrenia, comparing 2.5 mg to 20 mg per day of olanzapine to placebo over 4 weeks. The primary efficacy end point—the changes in the Brief Psychiatric Rating Scale-for Chil-

dren (BPRS-C) total score from baseline to end point—found a significantly greater effect among those on olanzapine, with an effect size comparable to that seen in adult studies, according to the company.

In another study of 161 patients aged 13-17 years with bipolar disorder who were in an acute manic or mixed episode, those who received 2.5 mg to 20 mg per day of olanzapine had reductions in the Young Mania Rating Scale (YMRS) total score (the primary efficacy end point) that were significantly greater than the reductions seen

among those on placebo, after 3 weeks of treatment.

In the two studies combined, sedation-related events were the most common adverse events associated with treatment (44% among those on olanzapine, compared with 9% of those on placebo), followed by increases in weight (almost 30%, compared with almost 6%, respectively), and increased appetite (24%, compared with 5.6%, respectively). Among those on olanzapine, 8% had elevated liver enzymes, compared with 1% of those on placebo.

The differences in these adverse events

were all significantly greater among the patients who were taking olanzapine.

In addition to weight gain, increases in fasting glucose, fasting total cholesterol, fasting triglycerides, and prolactin levels have been documented in adolescents treated with olanzapine for 12 weeks or less, and for longer durations, according to Eli Lilly.

The increased risks of weight gain, hyperlipidemia, hyperglycemia, and hyperprolactinemia associated with olanzapine use in adolescents are included in the drug's label, even though the drug has not been approved for this age group. ■

Votes Mixed on Ziprasidone for Pediatric Bipolar

ADELPHI, MD. — The atypical antipsychotic ziprasidone is effective for the treatment of manic or mixed episodes associated with bipolar disorder in patients aged 10-17 years, a Food and Drug Administration panel advised.

At a meeting in June, the Psychopharmacologic Drugs Advisory Committee voted 12-2 on ziprasidone's efficacy, with 4 abstentions. However, many on the 18-member panel abstained from voting on whether the data had shown the drug was acceptably safe in treating this population. Eight panel members voted in favor of safety, and one panelist voted no on this question. Among the reasons the nine panelists cited for abstaining was that a large number of patients were lost to follow-up in the study.

They also cited ambiguous data on an increase in QTc intervals among children treated with the drug, and the need for more data overall. Study data were presented by Pfizer, which manufactures ziprasidone (Geodon). The drug is already approved for treating schizophrenia and bipolar disorder in adults.

The panel was not asked specifically to rule on whether to recommend approval for treatment of the pediatric population. The FDA usually follows the recommendations of its advisory panels.

At the meeting, study results were presented on 238 patients, aged 10-17 years, with bipolar disorder (manic or mixed episodes) treated with placebo or ziprasidone (40-80 mg/day for those under 45 kg; 80-160 mg/day for those 45 kg or more). Based on the primary efficacy end point—change from baseline in the Young Mania Rating Scale after 4 weeks—there was a highly significant treatment effect similar to the changes observed in studies of adults, according to Pfizer.

Ziprasidone was generally well tolerated over 4 weeks, and for up to 26 weeks in an open-label study. The adverse event profile was similar to that seen in adults, with the exception of sedation and somnolence, which were more common in the pediatric population.

The rate of extrapyramidal symptoms was 24% among those on ziprasidone, compared with almost 8% among placebo. There were no completed suicides, and no increase in suicidality among those on ziprasidone.

In the short-term pediatric study, 3.6% of those on ziprasidone had a QTc interval increase of more than 450 msec vs. 1.2% of those on placebo, Pfizer said.

—Elizabeth Mechatie

FOR THE TOPICAL TREATMENT OF ACUTE PAIN
DUE TO MINOR STRAINS, SPRAINS, AND CONTUSIONS

NSAID POWER

that targets the site of acute pain



FLECTOR® Patch

- A unique way of delivering the proven efficacy of diclofenac in a patch that provides minimal systemic exposure^{1,2}
- Diclofenac is a nonsteroidal anti-inflammatory drug²



- Dispensed in boxes of 30 patches
- 2 weeks of therapy = 1 box
- 1 month of therapy = 2 boxes



FLECTOR® Patch is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.

Carefully consider the potential benefits and risks of FLECTOR® Patch and other treatment options before deciding to use FLECTOR® Patch. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.

Important Safety Information

Cardiovascular (CV) risk

- NSAIDs may cause an increased risk of serious CV thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with CV disease or risk factors for CV disease may be at greater risk
- FLECTOR® Patch is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery

Gastrointestinal (GI) risk

- NSAIDs cause an increased risk of serious GI adverse events at any time during use and without warning symptoms including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients are at greater risk for serious GI events

FLECTOR® Patch is contraindicated in patients with known hypersensitivity to diclofenac. FLECTOR® Patch should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.

FLECTOR® Patch should not be applied to non-intact or damaged skin resulting from any etiology, e.g., exudative dermatitis, eczema, infected lesion, burns or wounds.

NSAIDs, including FLECTOR® Patch, can lead to new onset or worsening of hypertension, contributing to increased incidence of CV events. Fluid retention and edema have been observed in some patients taking NSAIDs. Use with caution in patients with hypertension, fluid retention or heart failure.

A patient with symptoms and/or signs of liver dysfunction, or with a history of an abnormal liver test, should be monitored for a more severe hepatic reaction and therapy stopped. Anemia is sometimes seen in patients receiving NSAIDs and platelet inhibition has been shown to prolong bleeding times.

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in maintaining renal perfusion. FLECTOR® Patch is not recommended in patients with advanced renal disease.

NSAIDs, including FLECTOR® Patch, can cause serious skin adverse events without warning such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.

Overall, the most common adverse events associated with FLECTOR® Patch were skin reactions (pruritus, dermatitis, burning, etc.) at the site of treatment and gastrointestinal disorders (nausea, dysgeusia, dyspepsia, etc.) and nervous system disorders (headache, paresthesia, somnolence, etc.).

In late pregnancy, as with other NSAIDs, FLECTOR® Patch should be avoided because it may cause premature closure of the ductus arteriosus. FLECTOR® Patch is in Pregnancy Category C. Safety and effectiveness in pediatric patients have not been established.

Please see Brief Summary of full Prescribing Information, including boxed warning, on adjacent page.

For more information, please visit www.FlectorPatch.com or www.KingPharm.com.

References: 1. Data on file. King Pharmaceuticals®, Inc. 2. Flector Patch [package insert]. Piscataway, NJ: Alpharma Pharmaceuticals LLC; 2008.



FLECTOR is a registered trademark of Institut Biochimique SA.
Copyright © 2009 King Pharmaceuticals®, Inc. All rights reserved.
FLE5904 01/2009



(diclofenac epolamine topical patch) 1.3%

Targeted NSAID Power